Guided by
core values of
Emerging footprint in large molecules within biotechnology, cell and gene therapies
Global presence in
small-molecule
pharmaceutical ingredients
and finished dosages
Global presence in
small-molecule pharmaceutical
ingredients and finished dosages
Best-in-class, future-ready facilities staffed by meritorious personnel
Best-in-class, future-ready facilities staffed by meritorious personnel
Integrated processes for development, manufacturing, and supply-chain solutions
Committed to sustainable, efficient, and scalable operations
Committed to sustainable, efficient, and scalable operations
Impeccable regulatory
compliance track record
since the commencement
of operations.
Impeccable regulatory
compliance track record
since the commencement
of operations.
One quality standard for all markets.
Core emphasis on safety, environment, and society.
Core emphasis on safety, environment, and society.
Press releases and announcements
16 Sep 2024
Press Release - Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park
13 Sep 2024
Press Release - Laurus Labs Concludes Successful US FDA Audit for API Manufacturing Facility at Hyderabad
25 Jul 2024
Press Release - Laurus Labs Announces Q1 FY 25 Results Revenues at ₹ 1,195 Cr; EBITDA at ₹ 171 Cr
25 Apr 2024
Press Release - Financial results for the quarter and year ended March 31, 2024
25 Jan 2024
Press Release - JV Agreement with KRKA